Home        Sitemap        Contact us 
Technology Platform
 
You are in: » Technology Platform  » Medicinal Chemistry & Early Discovery
 
Medicinal Chemistry & Early Discovery
Arrien pharmaceutical's drug discovery objectives and success reflected from a multidisciplinary team of scientists with expertise in medicinal chemistry, computational, structural and cancer biology and pharmacology, and DMPK. The teamís vast experiences from pharmaceutical industry, which enabled to quickly execute companyís product pipeline in a short period of time. Arrien Pharmaceuticals cost-competent approach evolved from its FFDD technology and influenced the discovery of target-specific leads for multiple protein targets.

Moreover, the company technology has proven in the identification of potent and highly selective protein kinase inhibitors including non-kinase targets. The technology immensely involves empirical data coupled with the application proprietary FFDD workflows, ideal candidate property predictions, early phase safety pharmacology and target specific screening for novel chemical entities are critical to our successful drug discovery processes.
 
Copyright © 2011, Arrien Pharmaceuticals, LLC. All rights reserved.